microRNA-199a downregulation alleviates hyperuricemic nephropathy via the PPARγ/β-catenin axis

References

• Ichida K, Matsuo H, Takada T, et al. Decreased extra-renal urate excretion is a common cause of hyperuricemia. Nat Commun. 2012;3:764.
   PubMed Web of Science ®Google Scholar
• Johnson RJ, Bakris GL, Borghi C, et al. Hyperuricemia, acute and chronic kidney disease, hypertension, and cardiovascular disease: report of a scientific workshop organized by the national kidney foundation. Am J Kidney Dis. 2018;71(6):851–865.
   PubMed Web of Science ®Google Scholar
• Li X, Yan Z, Carlstrom M, et al. Mangiferin ameliorates hyperuricemic nephropathy which is associated with downregulation of AQP2 and increased urinary uric acid excretion. Front Pharmacol. 2020;11:49.
   PubMed Web of Science ®Google Scholar
• Thounaojam MC, Montemari A, Powell FL, et al. Monosodium urate contributes to retinal inflammation and progression of diabetic retinopathy. Diabetes. 2019;68(5):1014–1025.
   PubMed Web of Science ®Google Scholar
• Shi Y, Tao M, Ma X, et al. Delayed treatment with an autophagy inhibitor 3-MA alleviates the progression of hyperuricemic nephropathy. Cell Death Dis. 2020;11(6):467.
   PubMed Web of Science ®Google Scholar
• Shi M, Guo F, Liao D, et al. Pharmacological inhibition of fatty acid-binding protein 4 alleviated kidney inflammation and fibrosis in hyperuricemic nephropathy. Eur J Pharmacol. 2020;887:173570.
   PubMed Web of Science ®Google Scholar
• Lu J, Dalbeth N, Yin H, et al. Mouse models for human hyperuricaemia: a critical review. Nat Rev Rheumatol. 2019;15(7):413–426.
   PubMed Web of Science ®Google Scholar
• Li X, Pan X, Fu X, et al. MicroRNA-26a: an emerging regulator of renal biology and disease. Kidney Blood Press Res. 2019;44(3):287–297.
   PubMed Web of Science ®Google Scholar
• Lv W, Fan F, Wang Y, et al. Therapeutic potential of microRNAs for the treatment of renal fibrosis and CKD. Physiol Genomics. 2018;50(1):20–34.
   PubMed Web of Science ®Google Scholar
• Sun WF, Zhang XX, Sun FY, et al. MicroRNA expression patterns of the kidney in hyperuricemia mice treated with Xiezhuo Chubi decoction. Chin J Integr Med. 2011;17(1):35–42.
   PubMed Web of Science ®Google Scholar
• Yu S, Hong Q, Wang Y, et al. High concentrations of uric acid inhibit angiogenesis via regulation of the Krüppel-like factor 2-vascular endothelial growth factor-A axis by miR-92a. Circ J. 2015;79(11):2487–2498.
   PubMed Web of Science ®Google Scholar
• Estevez-Garcia IO, Gallegos-Nava S, Vera PE, et al. Levels of cytokines and microRNAs in individuals with asymptomatic hyperuricemia and ultrasonographic findings of gout: a bench-to-bedside approach. Arthritis Care Res. 2018;70(12):1814–1821.
   PubMed Web of Science ®Google Scholar
• Zhong X, Chen Y, Yao C, et al. MicroRNA-30b participates in the pathological process of hyperuricemia by regulating interleukin-6 receptor. Nucleosides Nucleotides Nucleic Acids. 2020;39(8):1162–1178.
   PubMed Web of Science ®Google Scholar
• Yan G, Li B, Xin X, et al. MicroRNA-34a promotes hepatic stellate cell activation via targeting ACSL1. Med Sci Monit. 2015;21:3008–3015.
   PubMed Web of Science ®Google Scholar
• Vandenbussche C, Van der Hauwaert C, Dewaeles E, et al. Tacrolimus-induced nephrotoxicity in mice is associated with microRNA deregulation. Arch Toxicol. 2018;92(4):1539–1550.
   PubMed Web of Science ®Google Scholar
• Wang C, Zhu G, He W, et al. BMSCs protect against renal ischemia-reperfusion injury by secreting exosomes loaded with miR-199a-5p that target BIP to inhibit endoplasmic reticulum stress at the very early reperfusion stages. FASEB J. 2019;33(4):5440–5456.
   PubMed Web of Science ®Google Scholar
• Lefterova MI, Haakonsson AK, Lazar MA, et al. PPARγ and the global map of adipogenesis and beyond. Trends Endocrinol Metab. 2014;25(6):293–302.
   PubMed Web of Science ®Google Scholar
• Wang S, Dougherty EJ, Danner RL. PPARγ signaling and emerging opportunities for improved therapeutics. Pharmacol Res. 2016;111:76–85.
   PubMed Web of Science ®Google Scholar
• Gutting T, Weber CA, Weidner P, et al. PPARγ-activation increases intestinal M1 macrophages and mitigates formation of serrated adenomas in mutant KRAS mice. Oncoimmunology. 2018;7(5):e1423168.
   PubMed Web of Science ®Google Scholar
• Kadam L, Gomez-Lopez N, Mial TN, et al. Rosiglitazone regulates TLR4 and rescues HO-1 and NRF2 expression in myometrial and decidual macrophages in inflammation-induced preterm birth. Reprod Sci. 2017;24(12):1590–1599.
   PubMed Web of Science ®Google Scholar
• Wang X, Deng J, Xiong C, et al. Treatment with a PPAR-γ agonist protects against hyperuricemic nephropathy in a rat model. Drug Des Devel Ther. 2020;14:2221–2233.
   PubMed Web of Science ®Google Scholar
• Bruen R, Fitzsimons S, Belton O. miR-155 in the resolution of atherosclerosis. Front Pharmacol. 2019;10:463.
   PubMed Web of Science ®Google Scholar
• Chhabra M, Sharma S. Potential role of peroxisome proliferator activated receptor gamma analogues in regulation of endothelial progenitor cells in diabetes mellitus: an overview. Diabetes Metab Syndr. 2019;13(2):1123–1129.
   PubMed Web of Science ®Google Scholar
• Chen RJ, Chen MH, Chen YL, et al. Evaluating the urate-lowering effects of different microbial fermented extracts in hyperuricemic models accompanied with a safety study. J Food Drug Anal. 2017;25(3):597–606.
   PubMed Web of Science ®Google Scholar
• Li L, Yang C, Zhao Y, et al. Is hyperuricemia an independent risk factor for new-onset chronic kidney disease? A systematic review and meta-analysis based on observational cohort studies. BMC Nephrol. 2014;15:122.
   PubMed Web of Science ®Google Scholar
• Zhang M, Cheng J, Sun Z, et al. Protective effects of carbon dots derived from phellodendri chinensis cortex carbonisata against deinagkistrodon acutus venom-induced acute kidney injury. Nanoscale Res Lett. 2019;14(1):377.
   PubMed Web of Science ®Google Scholar
• Cui D, Liu S, Tang M, et al. Phloretin ameliorates hyperuricemia-induced chronic renal dysfunction through inhibiting NLRP3 inflammasome and uric acid reabsorption. Phytomedicine. 2020;66:153111.
   PubMed Web of Science ®Google Scholar
• Wang G, Zuo T, Li R. The mechanism of arhalofenate in alleviating hyperuricemia-activating PPARγ thereby reducing caspase-1 activity. Drug Dev Res. 2020;81(7):859–866.
   PubMed Web of Science ®Google Scholar
• Liu B, Tan P. PPAR γ/TLR4/TGF-β1 axis mediates the protection effect of erythropoietin on cyclosporin A-induced chronic nephropathy in rat. Ren Fail. 2020;42(1):216–224.
   PubMed Web of Science ®Google Scholar
• Choi JH, Jin SW, Choi CY, et al. Capsaicin inhibits dimethylnitrosamine-induced hepatic fibrosis by inhibiting the TGF-beta1/SMAD pathway via peroxisome proliferator-activated receptor gamma activation. J Agric Food Chem. 2017;65(2):317–326.
   PubMed Web of Science ®Google Scholar
• Pan J, Shi M, Li L, et al. Pterostilbene, a bioactive component of blueberries, alleviates renal fibrosis in a severe mouse model of hyperuricemic nephropathy. Biomed Pharmacother. 2019;109:1802–1808.
   PubMed Web of Science ®Google Scholar
• Wang CY, Liu Q, Huang QX, et al. Activation of PPARgamma is required for hydroxysafflor yellow A of carthamus tinctorius to attenuate hepatic fibrosis induced by oxidative stress. Phytomedicine. 2013;20(7):592–599.
   PubMed Web of Science ®Google Scholar
• Vallee A, Lecarpentier Y, Guillevin R, et al. Opposite interplay between the canonical WNT/β-catenin pathway and PPAR gamma: a potential therapeutic target in gliomas. Neurosci Bull. 2018;34(3):573–588.
   PubMed Web of Science ®Google Scholar
• Tao M, Shi Y, Tang L, et al. Blockade of ERK1/2 by U0126 alleviates uric acid-induced EMT and tubular cell injury in rats with hyperuricemic nephropathy. Am J Physiol Renal Physiol. 2019;316(4):F660–F673.
   PubMed Web of Science ®Google Scholar
• Senouthai S, Wang J, Fu D, et al. Fractalkine is involved in lipopolysaccharide-induced podocyte injury through the Wnt/β-catenin pathway in an acute kidney injury mouse model. Inflammation. 2019;42(4):1287–1300.
   PubMed Web of Science ®Google Scholar
• Hao S, He W, Li Y, et al. Targeted inhibition of β-catenin/CBP signaling ameliorates renal interstitial fibrosis. J Am Soc Nephrol. 2011;22(9):1642–1653.
   PubMed Web of Science ®Google Scholar
• Zhou Z, Wan J, Hou X, et al. MicroRNA-27a promotes podocyte injury via PPARgamma-mediated beta-catenin activation in diabetic nephropathy. Cell Death Dis. 2017;8(3):e2658.
   PubMedGoogle Scholar
• Badawy AM, El-Naga RN, Gad AM, et al. Wogonin pre-treatment attenuates cisplatin-induced nephrotoxicity in rats: impact on PPAR-γ, inflammation, apoptosis and Wnt/β-catenin pathway. Chem Biol Interact. 2019;308:137–146.
   PubMed Web of Science ®Google Scholar